Condition (MeSH)
Sarcoma, Alveolar Soft Part
ClinicalTrials.gov lists 51 trials for Sarcoma, Alveolar Soft Part or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 10.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
51 of the 51 trials are tagged with Sarcoma, Alveolar Soft Part itself; the rest are tagged with a narrower condition beneath it.
When did Sarcoma, Alveolar Soft Part trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 30 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sarcoma, Alveolar Soft Part trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 5 |
| Phase 2 | 25 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |
| Not applicable | 2 |
| Observational | 1 |
How many Sarcoma, Alveolar Soft Part trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 9 |
| Active, not recruiting | 5 |
| Completed | 25 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sarcoma, Alveolar Soft Part trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 10 |
| European Organisation for Research and Treatment of Cancer - EORTC | 8 |
| AEterna Zentaris | 1 |
| Advenchen Laboratories, LLC | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Sarcoma, Alveolar Soft Part? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cediranib | 3 |
| Perifosine | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxorubicine | 6 |
| Ifosfamid | 5 |
| GCAR1 | 5 |
| Pazopanib Pill | 3 |
| Atezolizumab SC | 3 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sarcoma, Alveolar Soft Part trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 45 | 6 |
| Pleural effusion | 36 | 5 |
| Vomiting | 34 | 7 |
| Nausea | 28 | 6 |
| Fever | 27 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Sarcoma, Alveolar Soft Part? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. | The Lancet. Oncology | 2023 | Yes |
| Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | Yes |
| Atezolizumab for Advanced Alveolar Soft Part Sarcoma. | The New England journal of medicine | 2023 | Yes |
| Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. | The Lancet. Oncology | 2022 | Yes |
| A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. | The oncologist | 2019 | Yes |
Showing 5 of 19 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Alveolar soft tissue sarcoma | 163699 | Exact | Orphadata Science knowledge files, Product 1 |
| Alveolar soft tissue sarcoma | 163699 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.